Estrogen deficiency causes postmenopausal osteoporosis, the commonly seen osteoporosis. Deficiency of estrogen happens in a rise of the bone turnover due to the impacts of all kinds of bone cells. The disparity in formation of bones and the resorption has impact on the trabecular bone which causes connectivity loss and the cortical bone, leading to thinning and porosity. The measurements of the bone density in the lumbar spine and the proximal femur aids in diagnosing osteoporosis. The approaches that need to be undertaken in preventing osteoporosis are exercise, staying away from smoking and maintaining proper diet. Drugs like as bisphosphonates and Denosumab are licensed in lessening the risk of fracture, by reducing the bone resorption or by stimulation of formation of bones with drugs like teriparatide. Advanced understanding of the osteoporosis cellular basis has led in targeting novel drugs to the main way, which are still not developed.
Globally, the market for postmenopausal osteoporosis is projected to be priced at US$ 4,547.8 Mn in the year 2022 and is anticipated to show a CAGR of 4.4% in the predicted period from 2022 to 2030.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/5479
Analysts’ Views on the market of Postmenopausal Osteoporosis worldwide:
Globally, the market of postmenopausal osteoporosis is anticipated to develop in the coming future due to the strong array of drugs meant for treating postmenopausal osteoporosis, which raises the product’s consent number and launch of new product in the predicted period. For example, Radius Health, Inc., on 30th October 2022, pronounced that data from Phase 3 Abaloparatide in treating men having osteoporosis medical trial (NCT03512262) assessing abaloparatide in comparison to placebo was issued. TYMLOS (abaloparatide) is a parathyroid hormone-associated peptide for humans’ analog that has been already specified for treating postmenopausal women with osteoporosis having excessive risk to fracture. The positive study of ATOM was issued in the JBMR (Journal of Bone and Mineral Research). TYMLOS is a brilliant molecule whose usage can be a treatment option for postmenopausal osteoporosis patients.
Global Postmenopausal Osteoporosis Market- Drivers
Rising R&D activities amongst the companies in the market and the research institutes
The progress of the treatment meant for postmenopausal osteoporosis by means of augmented activities of R&D amongst the companies in the market and the research institute is anticipated to push the growth of the market in the predicted period. For example, Bone Health Technologies (BHT) is a company emphasized on bone disease therapies like osteoporosis pronounced on 8th June, 2022, that it will carry out a one year study of a new, non-drug intervention in treating osteopenia in postmenopausal women, in collaboration with the San Francisco Veterans Affairs Health Care System (SFVAHCS), San Francisco (UCSF), the University of California, and the Northern California Institute for Research and Education (NCIRE). Bone Health Technologies is planning to enroll 50 patients having varied racial and national backgrounds who at present are not consuming osteoporosis drugs, having dual-energy X-ray absorptiometry (DXA) scan bone density T-scores ranging from -1.0 and -2.4. This study will enable to recognize treatment choices and apt drug choices for treating of postmenopausal osteoporosis in the coming future.
Rising product consent by regulatory establishments
Rising product consents by regulatory establishments is anticipated to push the market growth of postmenopausal osteoporosis in the predicted period. For example, Radius Health, Inc., is a biopharmaceutical company which announced on 9th December 2022, that, the European Commission has approved marketing consent for abaloparatide under tradename of ELADYNOS in treating osteoporosis in postmenopausal women having more risk of fracture. In the U.S., abaloparatide got approved since April 2017 under name of TYMLOS.
Abaloparatide is a PTHrP (1-34) analog that excites new formation of bone on trabecular and cortical bone surfaces by stimulating osteoblastic activity that will lead in reducing new fractures. Abaloparatide is delivered as a single-patient multi-use prefilled pen which is intended to control 80 micrograms per dose in a period of 30-day.
Global Postmenopausal Osteoporosis Market – Regional Analysis
Amongst all regions, North America is anticipated to control the world market in the predicted period due to the supervision by multidisciplinary establishments. For example, the NAMS (North American Menopause Society) is a non-profit, multidisciplinary establishment which announced on 7th September 2021 a new position report charting the establishments supervision for managing osteoporosis in postmenopausal women. The report acclaims the use of T-score at the hip as an apt target in guidance to the therapy selection, as present proof states measurement on-treating of bone mineral density associates with the risk of the fracture of the patient. The report also states the different methods for women at great risk of fracture, which introduces the initiation of the treatment with a bone-building agent led by an anti-modelling agent, like bisphosphonates and Denosumab.
The region of Europe is anticipated to rank second in position of all region in the predicted period. For example, the U.K. National Institute for Health and Care Excellence (NICE) on 25th May, 2022, suggested the sclerostin inhibitor romosozumab that is used in treating for postmenopausal patients in Wales and England who had critical osteoporotic fracture in last 24months. Romosozumab is the class of drug which is found for treating osteoporosis in almost 10years and the maiden drug for osteoporosis in reducing bone resorption and excite formation of bone. The developers of the drug, Amgen and UCB, calculate that over 20,000 people in England and Wales could be fit for treatment.
We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/5479
Global Postmenopausal Osteoporosis Market– Impact of Coronavirus (COVID-19) Pandemic_MI
The COVID-19 outbreak in December 2019 showed the effect of the virus spread in more than 100 countries worldwide and the WHO announced it to be a state of public health emergency on 30thy January 2020.
COVID-19 impacted the country mainly in three ways- by impacting directly the demand and the manufacturing of drugs and vaccines, by interrupting the supply and the distribution channels and finally impacting the financial condition of the financial markets and the firms. Owing to the lockdowns in almost all the nations, mainly India, UAE, China, Saudi Arabia, Egypt and others encountered many problems with transporting vaccines and drugs from origin to its destination.
The pandemic of COVID-19 had adversely affected due to the lockdowns which created a negative effect on observing the Denosumab therapy. The pandemic adversely affected the medical results of the patients having osteoporosis with the current treatment of Denosumab, exhibiting a high incidence of non-observant patients and an increase in number of novel non-traumatic fractures, which also includes rebound fractures at the time of lockdown as compared to the time before COVID-19, irrespective of the modality of clinical assessment. Thus, tele-medicine is a good way to typical one-to-one appointments in assuring the steadiness of following up in the patient having osteoporosis and short-term agreement with Denosumab.
Global Postmenopausal Osteoporosis Market Segmentation
Globally, the market of postmenopausal osteoporosis is divided into Drug Class, Distribution Channel and Route of Administration.
On the basis of drug class, the market is divided into Selective Estrogen Receptor Modulators (SERMs), Anabolic Class, Calcium Metabolism Modifiers, Bisphosphonates, RANK Ligand Inhibitors, and Others (Calcitonin, Denosumab, among Others). Amongst which, the segment of Bisphosphonates is anticipated to control the market of postmenopausal osteoporosis in the predicted period and a rise in the application of Bisphosphonates for treating postmenopausal osteoporosis.
On the basis of route of administration, the market is divided into Intravenous Route, Oral, and Subcutaneous. Among which, the segment of oral is anticipated to control the market in the predicted period and the rise in usage of oral suspension in treating many diseases like the aforesaid one.
On the basis of distribution channel, the market for postmenopausal osteoporosis is divided into retail pharmacies, hospital pharmacies and online pharmacies. Amongst which, the segment of hospital pharmacies is anticipated to control the market in the predicted period and this is accredited to a rise in the figure of hospital pharmacies.
Global Postmenopausal Osteoporosis Market Cross Sectional Analysis
In the segment of drug class, the remaining segment is controlling the region of Europe owing to the rise in number of product consents by governing establishments like European Medicines Agency (EMA). For example, Stelis Biopharma which is the biologics arm of Strides Pharma Science Limited pronounced on 14th November, 2022, that the company’s product division Biolexis had great achievement with its first biosimilar product KaulivTM which got a successful approval from EMA (European Medicines Agency) to permit for market approval. KaulivTM is a recombinant teriparatide injection for human designed to treat osteoporosis. KaulivTM is a bio similar to Forsteo which is the innovator product, made both for postmenopausal women and men with osteoporosis and is at great risk of having fractures or broken bones.
Global Postmenopausal Osteoporosis Market: Key Developments
Innovent Biologics, Inc., is a renowned biopharmaceutical company and PT Etana Biotechnologies Indonesia is a biotechnology company based in Indonesia which announced together on 13th June, 2022, that the FDA (Badan Pengawas Obat dan Makanan) of Indonesian Food had permitted Bevagen (bevacizumab biosimilar) which is a recombinant improved anti-vascular endothelial factor of growth (anti-VEGF) monoclonal antibody drug, with five signs having mCRC(metastatic colorectal cancer), mTNBC (locally periodic or metastatic triple-negative breast cancer), NSCLC (recurrent non-small cell lung cancer), advanced, CC (cervical cancer), OC (epithelial ovarian, fallopian tube, and primary peritoneal cancer)
Global Postmenopausal Osteoporosis Market: Restraint
After effects from treatment of postmenopausal osteoporosis
The main issues that hamper the market growth of postmenopausal osteoporiosis are the after effects from its treatment. For example, an article was issued in JAMA which is journal reviewing reports of the peers, claimed on 5th January 2021, the after effects of treating with bisphosphonates for postmenopausal osteoporosis. It causes adverse effects commonly seen like lack of supply of blood to the jawbone called osteonecrosis of the jaw- a different kind of femoral fracture, and thigh high bone fracture in rare cases. Commonly caused osteonecrosis of the jaw is aggressive dental task like tooth extraction. Women consuming biosphosphonates should consult their doctor before taking this treatment whether it is required to stop its consumption. Over five years of bisphosphonate application increases the probability of the different kind of femoral fracture.
Global Postmenopausal Osteoporosis Market- Key Players
The main companies in the market of postmenopausal osteoporosis are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/5479
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Postmenopausal Osteoporosis Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Postmenopausal Osteoporosis Industry Impact
Chapter 2 Global Postmenopausal Osteoporosis Competition by Types, Applications, and Top Regions and Countries
2.1 Global Postmenopausal Osteoporosis (Volume and Value) by Type
2.3 Global Postmenopausal Osteoporosis (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Postmenopausal Osteoporosis Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America Postmenopausal Osteoporosis Market Analysis
Chapter 6 East Asia Postmenopausal Osteoporosis Market Analysis
Chapter 7 Europe Postmenopausal Osteoporosis Market Analysis
Chapter 8 South Asia Postmenopausal Osteoporosis Market Analysis
Chapter 9 Southeast Asia Postmenopausal Osteoporosis Market Analysis
Chapter 10 Middle East Postmenopausal Osteoporosis Market Analysis
Chapter 11 Africa Postmenopausal Osteoporosis Market Analysis
Chapter 12 Oceania Postmenopausal Osteoporosis Market Analysis
Chapter 13 South America Postmenopausal Osteoporosis Market Analysis
Chapter 14 Company Profiles and Key Figures in Postmenopausal Osteoporosis Business
Chapter 15 Global Postmenopausal Osteoporosis Market Forecast (2023-2030)
Chapter 16 Conclusions
Read Our More Related Reports:
Endocrine therapy drugs market
Global and china osteoporosis drugs market
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, United States
Phone: US +12067016702 / UK +4402081334027